Article
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
Cancer research - 15 May 2021
Yang Bin, Li Xi, Fu Yu, Guo Ensong, Ye Youqiong, Li Fuxia, Liu Si, Xiao Rourou, Liu Chen, Lu Funian, Huang Jia, Qin Tianyu, Han Leng, Peng Guang, Mills Gordon B, Sun Chaoyang, Chen Gang
Abstract excerpt
Mutant KRAS tumors are associated with poor outcomes, at least in part, due to decreased therapeutic sensitivity. Here, we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with PARP inhibitors (PARPi) and immune checkpoint blockade with anti-PD-L1 antibodies. In mutant KRAS tumors, inhibition of KRAS signaling with MEK inhibitors (MEKi) triggered and amplified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.